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The potency of therapeutic regimens containing human immunodeficiency virus (HIV) protease inhibitors is related to the
ability to maintain concentrations of drug in the plasma of patients that are sufficient for blocking viral replication. The
estimation of concentrations required for in vivo activity using in vitro assays is complicated by the fact that extensive binding
of many protease inhibitors to serum proteins attenuates their antiviral potency. To provide insight into the relative in vivo
potency of current protease inhibitors, we assayed their in vitro activity against wild-type and mutant HIV in the presence of
human serum (HS). Using this assay, ABT-378, a new protease inhibitor with trough levels in humans far in excess of the EC50
in the presence of 50% HS, was identified. The antiviral activity of ABT-378 was only modestly attenuated by HS, in contrast
to ritonavir, saquinavir, and nelfinavir. Examination of the effect of individual serum components suggested that the activity
of ABT-378 is affected predominantly by binding to a1-acid glycoprotein (AGP) while the activity of ritonavir is modulated by
both AGP and albumin. The method described here may provide insight into the in vivo potency of protease inhibitors and
be useful for the preclinical evaluation and selection of new protease inhibitors for clinical studies. © 1998 Academic Press
INTRODUCTION
The genome of the human immunodeficiency virus
(HIV) encodes an aspartic protease which is responsible
for the processing of the gag and gag-pol gene products
of HIV (Pearl and Taylor, 1987a,b). The critical role of HIV
protease in the replication cycle of HIV was initially
demonstrated by the site-directed mutagenesis of the
catalytic aspartate residues (Kohl et al., 1988). Four HIV
protease inhibitors are now licensed for the treatment of
HIV infection and several more are being developed.
Treatment with a potent protease inhibitor, e.g., ritonavir,
produces a rapid fall in plasma HIV RNA and corre-
sponding increase in CD4 cells (Danner et al., 1995;
Markowitz et al., 1995). However, the maximal effect of
protease inhibitor monotherapy is eventually lost in many
patients due to the development of resistance mutations
in the protease gene. The durability of virological re-
sponse is greater with higher doses of protease inhibi-
tors, establishing a general relationship between drug
exposure and the suppression of viral replication in vivo.
More specifically, the rate of appearance of resistance
mutations during monotherapy with ritonavir was found
to inversely correlate with the minimum (trough) plasma
drug concentrations rather than with dose (Molla et al.,
1996). Thus the virological potency of antiretroviral ther-
apy using protease inhibitors may be directly related to
the degree that levels in the blood and other infected
tissues are sustained in excess of those required to
effectively block replication.
The detailed understanding of the pharmacology of
protease inhibitors requires a reliable estimate of their in
vivo potency as well as accurate measurement of their
pharmacokinetic profile in humans. Distribution of pro-
tease inhibitors from the plasma into HIV-infected tis-
sues is dependent on the free drug concentration and
hence a function of binding of the drug to serum proteins.
Studies in animals (Cars et al., 1981; Peterson et al.,
1989), in vitro models (Peterson et al., 1984), and humans
(Wise, 1986; Shyu et al., 1988) have shown that high
serum protein binding significantly affects the kinetics of
extravascular distribution of many drugs. In vitro anti-HIV
assays that do not include human serum proteins may
thus overestimate the in vivo activity of protease inhibi-
tors that are highly protein bound (Kageyama et al., 1994;
Bilello et al., 1995, 1996). The attenuation of potential
activity is substantial with those agents whose binding
constant to serum proteins is large (.105 M21) and
whose apparent volume of distribution is small (Blas-
chke, 1977; Keller et al., 1984; Rowland, 1984; Meijer and
Van Der Sluijs, 1987). Notably, clinical evaluation of the
protease inhibitor SC-52151 produced no significant ef-
fect on plasma viral RNA despite high in vitro potency
and reasonable pharmacokinetics (Fischl et al., 1997),
apparently as a consequence of very high serum protein
binding (Lazdins et al., 1997). The most important abun-
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dant proteins in plasma are human serum albumin
(HSA), a-1 acid glycoprotein (AGP), and lipoproteins (LI-
POs). HSA, largely responsible for plasma binding of
acidic drugs, is the most abundant protein (40 mg/ml) in
plasma, whereas normal AGP level varies between
about 0.5–1 mg/ml of plasma. AGP and LIPO primarily
bind basic and neutral drugs. Previous in vitro studies on
the protease inhibitors KNI-272, A-77003, and A-80987
demonstrated a significant diminution of antiviral activity
in the presence of AGP (Kageyama et al., 1994; Bilello et
al., 1995, 1996). A recent comparative study identified a
substantial attenuation of the potency of saquinavir,
ritonavir, amprenavir, and SC-52151 by AGP against a
laboratory HIV strain in lymphocyte cultures (Lazdins et
al., 1997).
Recently we adapted our in vitro anti-HIV assay to
include whole human serum as a first step toward de-
veloping a model for the realistic assessment of the in
vivo activity of protease inhibitors. In the presence of 50%
HS, the activity of ritonavir was significantly attenuated.
This analysis was expanded to also include evaluation of
other protease inhibitors against both wild-type (wt) and
mutant HIV molecular clones. Consistently, the activity of
ritonavir, saquinavir, and nelfinavir was substantially af-
fected by the presence of HS, while the potency of
amprenavir and indinavir was moderately or only slightly
influenced, respectively. Using this assay, we identified a
potent, second-generation inhibitor, ABT-378, whose in
vitro activity was only modestly attenuated by binding to
HS. Further we evaluated the effects of individual serum
proteins (HSA and AGP) on the potency of ritonavir and
ABT-378. These studies provide an estimate of the in vivo
potency of currently available protease inhibitors as well
as information for the rational design of antiretroviral
regimens containing ABT-378 that are highly suppressive
of viral replication in vivo.
RESULTS
Effect of HS on the activity of protease inhibitors
toward wt and resistant HIV
To gauge the effect of serum protein binding on the
anti-HIV activity of protease inhibitors, we first evaluated
the production of infectious virus from HIV-infected lym-
phocytes in the presence of HS. CEM-HuS cells have
been reported to sustain HIV infection at HS concentra-
tions up to 50% (Bilello et al., 1995). We found that 50% HS
plus 10% FBS only modestly affected the cytopathic effect
of HIV on MT4 cells using MTT uptake (Pauwels et al.,
1988) as an indicator. Accordingly, we determined the
EC50 of ritonavir in MT4 cells in the presence of various
concentrations of HS (plus 10% FBS). As shown in Fig. 1,
increasing concentrations of HS significantly affected the
antiviral activity of ritonavir such that at 50% HS, the EC50
value was ca. 20-fold higher than that observed with 0%
HS. Intermediate concentrations of HS provided interme-
diate EC50 values, although the relationship between the
percent of HS and the change in EC50 was not linear.
Using this assay, we evaluated the effect of 50% HS on
the activity of ritonavir, saquinavir, indinavir, nelfinavir,
and amprenavir against several wt laboratory HIV-1
strains (Table 1). On average, the EC50 of ritonavir in-
creased by 19-fold in the presence of serum. Similarly,
the average potency of saquinavir and nelfinavir was
markedly attenuated (25- and 35-fold, respectively) by the
presence of serum. In contrast, the EC50 of indinavir was
nearly unaffected by serum binding (twofold average
change in EC50), and the activity of amprenavir was only
modestly (sixfold) affected.
We further examined the activity of the panel of HIV
protease inhibitors against viral clones containing spe-
cific mutations in HIV protease that were observed dur-
ing ritonavir (Molla et al., 1996) or saquinavir (Jacobsen et
al., 1995) monotherapy. EC50 values for each inhibitor
against seven single-mutant molecular clones and three
double mutants were determined in MT4 cells in the
presence or absence of 50% HS (Table 1). In general, the
sensitivity of the single or double mutants to each inhib-
itor was similar to that of the corresponding wild-type
clone (pNL4–3), as observed previously (Molla et al.,
1996). The median fold difference in EC50 between 0 and
50% HS for the 10 mutant viruses for each inhibitor was
the following: ritonavir, 24 (range 14–41); saquinavir, 33
(range 9–54); indinavir, 1.8 (range 1.2–4.1); nelfinavir, 38
(range 23–64); and amprenavir, 8.7 (range 4.6–14). A
similar trend was observed (Table 1) with viruses con-
structed to contain the multiple mutations during virolog-
ical rebound on ritonavir (V82T, A71V, I54V, M36I, E35D
and V82T, A71V, I54V, M36I, E35D, K20R) and indinavir
(V82T, I84V, L63P, M46I and V82T, I84V, L63P, M46I,
L10R). Thus the effect of human serum was consistent
over a broad range of inhibitor concentrations against
both sensitive and resistant virus. Taken together, these
results suggest that the antiviral potency of ritonavir,
FIG. 1. Effect of human serum on the antiviral activity of ritonavir in
vitro. Anti-HIV-1IIIB activity was determined in MT4 cells using the
uptake of MTT as an indicator of the cytopathic effect of HIV. Filled
squares, 0% HS (EC50 5 0.045 mM); open squares, 12% HS (EC50 5
0.22 mM); filled circles, 25% HS (EC50 5 0.34 mM); open circles, 50% HS
(EC50 5 0.57 mM).
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saquinavir, and nelfinavir is significantly attenuated in
vivo by plasma protein binding. In contrast, the in vivo
potency of indinavir may be more accurately represented
by in vitro virological assays in the absence of HS.
Characterization of the antiviral activity of ABT-378
against wt and resistant HIV
The above results suggest that in vitro virological as-
says that contain only fetal bovine serum may overesti-
mate the in vivo potency of protease inhibitors. As part of
our search for new inhibitors with properties superior to
current agents, we therefore adapted our routine assay
for the virological evaluation of new protease inhibitors
to include both 0 and 50% HS. This modification allowed
the investigation of structure-function relationships with
regard to serum protein binding and led ultimately to
identification of a second-generation protease inhibitor,
ABT-378 (Sham et al., 1998). The activity of ABT-378
against both wt and mutant HIV clones was compared to
that of current inhibitors (Table 1). In contrast to ritonavir,
the activity of ABT-378 toward wt HIV was affected by
50% HS only by an average of 5.3-fold. Thus in the
absence of HS, the EC50 of ABT-378 averaged fourfold
lower than that of ritonavir, reflecting the lower Ki of
ABT-378 toward HIV protease (Sham et al., 1998). In the
presence of serum, however, the average EC50 of ABT-
TABLE 1
Susceptibility of Wild-Type and Mutant Molecular Clones to a Panel of HIV Protease Inhibitors in the Absence or Presence of 50% Human Serum
Virus clone
Percent
HS
EC50 (mM)
a
Ritonavir Saquinavir Indinavir Nelfinavir Amprenavir ABT-378
wt (IIIB)b 0 0.058 6 0.014 0.011 6 0.003 0.038 6 0.008 0.011 6 0.004 0.066 6 0.003 0.017 6 0.004
50 1.04 6 0.31 0.18 6 0.06 0.059 6 0.012 0.32 6 0.11 0.29 6 0.01 0.10 6 0.04
wt (pNL4-3)b 0 0.076 6 0.024 0.021 6 0.007 0.053 6 0.008 0.037 6 0.016 0.10 6 0.020 0.022 6 0.004
50 1.66 6 0.29 0.68 6 0.17 0.10 6 0.04 1.34 6 0.28 0.98 6 0.24 0.13 6 0.03
wt (HXB2)b 0 0.071 6 0.036 0.009 6 0.004 0.031 6 0.008 0.028 6 0.011 0.068 6 0.020 0.012 6 0.003
50 1.31 6 0.62 0.25 6 0.06 0.10 6 0.05 1.11 6 0.30 0.37 6 0.05 0.05 6 0.01
V82Ac 0 0.20 6 0.03 0.013 6 0.001 0.088 6 0.012 0.040 6 0.007 0.11 6 0.03 0.033 6 0.012
50 4.08 6 0.35 0.39 6 0.15 0.14 6 0.05 2.33 6 0.40 0.67 6 0.00 0.27 6 0.05
V82Fc 0 0.25 6 0.06 0.015 6 0.003 0.094 6 0.024 0.13 6 0.06 0.19 6 0.07 0.026 6 0.008
50 3.60 6 0.32 0.42 6 0.10 0.13 6 0.01 4.41 6 0.58 1.88 6 0.22 0.15 6 0.04
V82Tc 0 0.22 6 0.05 0.007 6 0.001 0.084 6 0.010 0.034 6 0.014 0.062 6 0.003 0.031 6 0.009
50 5.64 6 0.49 0.12 6 0.00 0.098 6 0.028 1.23 6 0.10 0.87 6 0.11 0.15 6 0.03
V82Sc 0 0.30 6 0.10 0.012 6 0.004 0.078 6 0.004 0.056 6 0.012 0.088 6 0.004 0.026 6 0.005
50 9.22 6 0.53 0.32 6 0.07 0.12 6 0.02 2.34 6 0.41 0.87 6 0.12 0.31 6 0.04
G48Vc 0 0.11 6 0.01 0.043 6 0.004 0.091 6 0.014 0.091 6 0.026 0.21 6 0.05 0.008 6 0.001
50 1.71 6 0.25 1.96 6 0.25 0.11 6 0.02 3.67 6 0.55 1.74 6 0.46 0.16 6 0.03
I84Vd 0 0.14 6 0.02 0.029 6 0.009 0.041 6 0.009 0.048 6 0.008 0.35 6 0.09 0.020 6 0.005
50 2.70 6 0.29 0.26 6 0.04 0.086 6 0.043 2.30 6 0.30 2.89 6 0.65 0.17 6 0.03
L90Mc 0 0.093 6 0.004 0.017 6 0.008 0.065 6 0.012 0.12 6 0.04 0.10 6 0.04 0.016 6 0.004
50 2.29 6 0.28 0.62 6 0.08 0.14 6 0.04 2.67 6 0.79 0.94 6 0.24 0.18 6 0.02
V82A, I54Vc 0 0.045 6 0.012 0.019 6 0.012 0.041 6 0.003 0.049 6 0.001 0.097 6 0.004 0.013 6 0.002
50 1.83 6 0.21 0.76 6 0.25 0.17 6 0.03 3.16 6 0.86 1.13 6 0.07 0.13 6 0.01
V82F, I54Vc 0 0.077 6 0.010 0.018 6 0.006 0.054 6 0.011 0.054 6 0.006 0.20 6 0.04 0.021 6 0.003
50 1.83 6 0.50 0.94 6 0.32 0.26 6 0.07 1.77 6 0.17 0.92 6 0.00 0.20 6 0.02
V82T, I54Vc 0 0.13 6 0.04 0.014 6 0.008 0.034 6 0.011 0.048 6 0.005 0.063 6 0.014 0.013 6 0.001
50 3.41 6 0.96 0.76 6 0.43 0.12 6 0.06 1.25 6 0.24 0.31 6 0.04 0.22 6 0.03
V82T, A71V, I54V, M36I, E35Dd 0 1.10 6 0.80 0.026 6 0.01 0.22 6 0.02 0.13 6 0.03 0.035 6 0.008 0.083 6 0.016
50 35 6 1.2 0.63 6 0.06 0.38 6 0.04 4.19 6 0.99 0.53 6 0.14 0.69 6 0.06
V82T, A71V, I54V, M36I, E35D,
K20Rd 0 1.46 6 0.12 0.018 6 0.003 0.21 6 0.05 0.16 6 0.06 0.041 6 0.014 0.093 6 0.014
50 17 6 1.0 0.89 6 0.06 0.31 6 0.05 5.39 6 1.27 0.25 6 0.02 0.38 6 0.05
V82T, I84V, L63P, M46Ie 0 1.20 6 0.04 0.031 6 0.005 0.52 6 0.08 NDf NDf 0.20 6 0.02
50 63 6 18 1.40 6 0.24 1.26 6 0.14 NDf NDf 1.50 6 0.32
V82T, I84V, L63P, M46I, L10Re 0 1.20 6 0.10 0.034 6 0.005 0.65 6 0.08 0.056 6 0.024 NDf 0.16 6 0.01
50 42 6 14 1.70 6 0.42 1.50 6 0.23 2.52 6 0.26 2.01 6 0.32 1.20 6 0.20
a Values 6 standard deviation, represent the mean of at least two triplicate determinations.
b wt, wild type.
c Derived from pNL4-3 wild-type clone.
d Derived from HXB2 wild-type clone.
e Background undefined (obtained from the AIDS Depository, National Institute of Allergy and Infectious Diseases).
f ND, not determined.
257HUMAN SERUM ATTENUATES PROTEASE INHIBITORS ACTIVITY
378 was 14-fold lower than that of ritonavir. Against the
above panel of 10 single or double mutant clones, the
median effect of 50% HS on the activity of ABT-378 was
9.8-fold (range 4.8–20), and the EC50 of ABT-378 in the
presence of serum averaged 18-fold lower than that of
ritonavir.
The activity of ABT-378 against viral clones with mul-
tiple mutations declined by ca. 10-fold compared to wt
HIV (Table 1). As with wt and singly mutant virus, the
attenuation of potency of ABT-378 by 50% HS was mod-
est (four- to eightfold). Importantly, in the presence of 50%
HS, the EC50 of ABT-378 against the viral clones contain-
ing multiple mutations was equal to or lower than the
EC50 of ritonavir against the wild-type clones, suggesting
that plasma levels of ABT-378 equal to or above those
observed clinically with ritonavir (Hsu et al., 1997) will be
efficacious against ritonavir-resistant HIV in vivo.
Effect of binding by purified human serum
components on the antiviral activity of ABT-378 and
ritonavir
In an attempt to further characterize the effect of HS on
the in vitro anti-HIV activity of ABT-378 and ritonavir, the
EC50 of both compounds was determined in the absence
or presence of increasing concentrations of purified HSA
and AGP (Table 2). In the presence of 0.8 mg/ml of AGP,
which is equivalent to the concentration of AGP in normal
human serum, the EC50 values for ritonavir and ABT-378
were increased by 9- and 13-fold, respectively. In con-
trast, the presence of 25 mg/ml of HSA (60% of levels in
normal human serum) significantly altered the potency of
ritonavir but did not affect the activity of ABT-378. We
were unable to increase the levels of HSA further or to
combine purified HSA and AGP without compromising
the viability of the MT4 cells.
We also examined the binding of ritonavir and ABT-378
to purified AGP and HSA using equilibrium dialysis (Fig.
2). Each compound was extensively bound to both serum
components at #10 mM inhibitor concentrations. In the
presence of 0.8 mg/ml of AGP, the unbound portion of
ABT-378 and ritonavir (#0.73 and #3.8%, respectively)
did not change appreciably between 0.1 and 3 mM.
Above 3 mM, the unbound portion of both compounds
increased in a concentration-dependent manner, indicat-
ing saturation of AGP binding. The unbound portion of
ABT-378 in the presence of AGP was lower by two- to
fourfold than that of ritonavir at all concentrations. In
contrast, the free fraction of ABT-378 in the presence of
HSA (3.7–9.4%) was ca. 10-fold higher than that of ritona-
vir (0.3–2.1%). Taken together, these results suggest that
AGP is principally responsible for the attenuation of an-
tiviral activity of ABT-378 in the presence of 50% HS but
that both AGP and HSA contribute to the attenuation in
the potency of ritonavir.
DISCUSSION
In the absence of animal models for HIV infection in
humans, the ability to extrapolate from in vitro antiviral
activity of new antiretroviral agents and reliably estimate
activity in vivo is important for the identification of new
drug candidates. This need is particularly significant for
agents, such as HIV protease inhibitors, that are hydro-
phobic and often highly bound to human serum proteins.
Previously, binding to AGP has been shown to attenuate
the anti-HIV activity of several protease inhibitors in vitro
(Kageyama et al., 1994; Bilello et al., 1995, 1996). Recently
a comparative study of six protease inhibitors (saquina-
vir, indinavir, ritonavir, amprenavir, SC 52151, and CGP
61755) evaluated the effect of AGP on the antiviral activity
in wild-type HIV-infected MT-2 cells and primary lympho-
cytes (Lazdins et al., 1997). In this study, we use a
method wherein either whole, untreated human serum or
purified serum protein components are added to an
immortalized lymphocyte culture assay. Using this assay,
FIG. 2. Binding of ritonavir and ABT-378 to human serum albumin and
a1-acid glycoprotein as a function of protease inhibitor concentration.
Binding was performed using equilibrium dialysis using 25 mg/ml of
HSA or 0.8 mg/mL of AGP. Open circles, ritonavir; filled circles, ABT-
378.
TABLE 2
Anti-HIV Activity of Ritonavir and ABT-378 in the Presence of
Purified Human Serum Proteins
Serum proteina
EC50 (mM)
Ritonavir ABT-378
None 0.046 0.015
HSA (12.5 mg/mL) 0.15 0.011
HSA (25 mg/mL) 0.20 0.020
AGP (0.25 mg/mL) 0.14 0.069
AGP (0.50 mg/mL) 0.28 0.13
AGP (0.80 mg/mL) 0.42 0.19
a HSA, human serum albumin; AGP, a1 acid glycoprotein.
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we measured the activity of six HIV protease inhibitors
currently licensed or under clinical development against
both wild-type and mutant HIV molecular clones. Impor-
tantly, the addition of 50% HS affected the in vitro potency
of different inhibitors to varying degrees, in agreement
with the relative serum protein binding determined by
direct methods. Thus the activity of indinavir, which is
only 50% bound to HS (Vacca et al., 1994), was attenu-
ated only twofold in this assay, whereas the potency of
ritonavir, which is ca. 99% bound (Denissen et al., 1997),
declined by ca. 20-fold in the presence of serum. A
marked decline in the activity of saquinavir and nelfinavir
was also observed, along with a moderate effect on the
potency of amprenavir. We observed a similar effect of
HS with wild-type and mutant, highly resistant HIV. Qual-
itatively, our results are in agreement with those of Laz-
dins et al. (1997) who observed a substantial (11- to
17-fold) loss of activity of ritonavir, saquinavir, and am-
prenavir in MT-2 cells upon the addition of AGP and only
a twofold decline in the activity of indinavir.
The activity of protease inhibitors in the presence of
HS may provide an estimate of their in vivo potency that
is more realistic than values obtained in in vitro assays
that contain only 10% fetal bovine serum. In conjunction
with the pharmacokinetic profiles of each inhibitor, ‘‘pro-
tein-adjusted’’ EC50 values may provide a more complete
understanding of the virological response to different
protease inhibitors. For example, both ritonavir and indi-
navir produce a rapid and profound decline in plasma
viral RNA in HIV-infected individuals, even when used as
monotherapy (Danner et al., 1995; Markowitz et al., 1995;
Stein et al., 1996). Mean trough plasma levels of ritonavir
(5.1 mM) in patients between doses using 600 mg b.i.d.
are 21-fold higher than those of indinavir using 800 mg
q8h (0.25 mM) (Stein et al., 1996; Hsu et al., 1997). In the
absence of serum, the in vitro potency of the two drugs
differs by less than twofold. In the presence of 50% HS,
however, the EC50 of indinavir is 18-fold lower than that of
ritonavir. Thus the average Cmin of both inhibitors exceed
the measured protein-adjusted EC50 by four- to fivefold.
In contrast, treatment with saquinavir (600 mg t.i.d. dosed
as hard capsule formulation), which produces a maxi-
mum plasma concentration (Cmax) only ca. threefold over
the protein-adjusted EC50 and a decline to unquantifiable
levels between doses (Noble and Faulds, 1996), is active
in vivo only in combination with other antiretroviral
agents. Similarly, the Cmin of SC 52151 (0.5 mM), which
produced no virological response as monotherapy (Fis-
chl et al., 1997), exceeded its EC95 in the absence of
serum but was significantly less than its EC50 in the
presence of AGP (Lazdins et al., 1997). The results of this
study, together with the observation that high trough
levels reduce the rate of appearance of mutations in HIV
protease in patients on protease inhibitor monotherapy
(Molla et al., 1996) suggests that the ratio of sustained
plasma levels to the protein-adjusted activity of protease
inhibitors may provide a model for in vivo potency.
The use of this assay for screening possible drug
candidates enabled the identification of ABT-378, which
displays an EC50 in 50% HS more than 10-fold lower than
that of ritonavir. In contrast to ritonavir, saquinavir, or
nelfinavir, the attenuation of ABT-378 potency by HS was
moderate (5- to 10-fold) and similar to that observed with
amprenavir. As a result, the total concentration of ABT-
378 required to inhibit wt HIV-1 replication in tissue
culture in the presence of HS was lower than any current
protease inhibitor except indinavir. The free fraction of
ABT-378 in the presence of AGP was somewhat lower
than the free fraction of ritonavir (Fig. 2), and the antiviral
activity of ABT-378 was attenuated by AGP to a greater
degree than that of ritonavir (Table 2). However, the free
fraction of ABT-378 in the presence of HSA was much
(10-fold) higher than that of ritonavir. Furthermore, the
activity of ritonavir declined ca. fivefold in the presence of
HSA, while the activity of ABT-378 was unaffected. Taken
together, these results suggest that the modest attenu-
ation of the activity of ABT-378 in 50% HS is primarily a
result of binding to AGP, while the substantial decline of
ritonavir activity is due to binding to both proteins. In vitro
assays that only measure the effect of AGP may thus
underestimate the effect of whole serum on the activity of
a given protease inhibitor. The attenuation of antiviral
activity by serum binding may also be partially overcome
at high plasma concentrations if binding is saturated.
The free fraction of ABT-378 in the presence of AGP
quadrupled between drug concentrations of 3 and 10
mM. Since plasma levels of ABT-378 in that range in
patients are anticipated (vide infra), the measured anti-
viral activity in the presence of 50% HS might underes-
timate the activity of ABT-378 in vivo.
The in vitro activity of an inhibitor in the presence of
HS may provide insight into the concentration in the
plasma of patients that must be achieved and main-
tained to produce potent suppression of plasma HIV
RNA. The plasma concentration of ABT-378 in human
volunteers following a 400-mg single dose coadminis-
tered with 50 mg of ritonavir exceeded 2 mM for .12 h
(Sham et al., 1998). This value is .20-fold above the EC50
for ABT-378 against wild-type HIV and at least twofold
above the EC50 for ritonavir and indinavir-resistant HIV. In
contrast, the Cmin of both ritonavir and indinavir falls
significantly below their respective protein-adjusted
EC50 values for resistant HIV. These results suggest that
ABT-378, coadministered with small amounts of ritonavir
to enhance its pharmacokinetic profile (Kempf et al.,
1997; Sham et al., 1998) may provide a regimen that is
significantly more effective than currently available pro-
tease inhibitor regimens. Clinical investigation of the
safety and efficacy of ABT-378 in HIV-infected individuals
is in progress.
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MATERIALS AND METHODS
Determination of anti-HIV activity
MT4 cells were infected with 0.003 m.o.i. of HIV-1 at
1 3 106 cells/ml for 1 h, washed twice to remove unad-
sorbed virus, resuspended to 1 3 105 cells/ml of me-
dium, seeded in a 96-well plate at 100 mL/well, and
treated with an equal volume of a 1% dimethylsulfoxide
(DMSO) solution of inhibitor in a series of half log dilu-
tions in RPMI containing 10% fetal bovine serum (FBS), in
triplicate. The virus control culture was treated in an
identical manner except no inhibitor was added to the
medium. The cell control was incubated in the absence
of inhibitor or virus. Plates were incubated for 5 days in
a CO2 incubator at 37°C. On Day 5, stock solution of MTT
(4 mg/ml in PBS, Sigma) was added to all wells at 25 ml
per well. Plates were further incubated for 4 h, then
treated with 20% sodium dodecyl sulfate (SDS) plus 0.2 N
HCl at 50 ml per well to lyse the cells. After an overnight
incubation, optical density was measured by reading the
plates at 570/650-nm wave lengths on a Bio-Tek microti-
tre plate reader. Percent cytopathic effect (CPE) reduc-
tion was calculated from the formula below:
$~O.D. test well 2 O.D. infected control well!/
~O.D. uninfected control well
2 O.D. infected control well!% 3 100
EC50 values were determined from the plot of log (Fa/Fu)
vs. log (compound concentration) using the median-
effect equation by Chou (1991) where Fa is the fraction
inhibited by the compound and Fu is fraction uninhibited
(1 2 Fa).
Determination of the effect of human serum on the
anti-HIV activity of protease inhibitors
To analyze the effect of human serum (HS) and human
serum proteins on the antiviral activity of ABT-378, addi-
tional assays were performed in the presence of HS or
purified human serum proteins. Using the modification of
the MTT colorimetric method (Pauwels et al., 1988), the
above antiviral assay was performed in 96-well tissue
culture plates containing 50% HS (Sigma) plus 10% FBS
(Gibco/BRL, Grand Island, NY) or different concentra-
tions of HS proteins without whole serum. Compounds
were dissolved in DMSO, diluted at half log concentra-
tions in DMSO, then transferred to media without serum
at four times the final concentration, keeping the DMSO
concentration constant at 2%. These solutions were
added to 96-well plates at 50 ml per well in triplicates.
Cells were separately infected with 0.003 m.o.i. of HIV-1
at 1 3 106 cells/ml for 1 h, washed twice to remove
unadsorbed virus particles, and resuspended to 2 3 105
cells/ml in media without serum. The cell suspension (50
ml) was seeded at 1 3 104 cells per well. Uninfected cells
were included as control. Final DMSO concentration in
all wells was 0.5% including uninfected and infected
control wells. Cultures were incubated for 5 days in a
CO2 incubator at 37°C. EC50 values were measured
using MTT uptake as described above.
Determination of activity against mutant HIV-1
molecular clones
Single mutant viruses were constructed at specific
sites within the protease coding region by PCR using
mismatched pairs of primers. Proviral clones were con-
structed by subcloning of the 599 bp ApaI–BsmBI frag-
ment containing the mutated protease gene into a cas-
sette shuttle vector (pNL4–3) (generous gift from DuPont
Merck). The mutant molecular clones were used to trans-
fect MT4 cells. For the construction of multiple mutant
clones, RNA was isolated from the plasma of patients on
ritonavir therapy, amplified by RT–PCR using primers for
HIV protease, cloned into a TA vector, and sequenced.
The mutant protease gene fragments thus obtained were
cotransfected with a HXB2 protease deletion clone
(Molla et al., 1996). After 48 h the supernatants were
assayed for p24 expression and where positive, used to
infect MT4 cells. The complete sequence of the protease
gene from the mutant viral population was confirmed by
DNA sequencing. For drug susceptibility assays, viral
supernatants were propagated, titered, and utilized in
MT4 cells according to the method described above.
Protein binding analysis
Ritonavir was synthesized with a uniform 14C-label in
the valine moiety of the molecule and stored in ethanol
(61.4 mCi/mg). ABT-378 was uniformly labeled with 14C in
the carbonyl carbon b to the 2,6-dimethylphenoxy group
of the molecule by Dr. J. Uchic of Abbott Laboratories and
stored in ethanol (88.2 mCi/mg). Three radiolabeled stock
solutions of either ritonavir or ABT-378 having final con-
centrations of 0.01, 0.1, and 1.0 mg/ml were prepared in
methanol. Radiochemical purity and stability studies
were performed using an Hewlett-Packard 1050 liquid
chromatography system consisting of a quaternary pump
(Hewlett-Packard, Wilmington, DE) and a Beckman Ultra-
sphere 5 mm 4.6 3 250 mm C18 column (Beckman
Instruments, Fullerton, CA). A linear gradient of 25–55%
acetonitrile in buffer (25 mM ammonium acetate, pH
adjusted to 4.8 with formic acid) over 57 min was used as
column eluent at a flow rate of 1 ml/min. Radioactivity in
the column effluent was monitored with a Flo-One/Beta
Model A-500 radioactivity flow detector (Packard Instru-
ment, Meriden, CT) equipped with a 0.25-ml flow cell. A
ratio of column effluent to liquid scintillator (Ultima Flo M,
Packard Instruments) of 1:3 was used. The radioactive
purity of the stock solutions of both ritonavir and ABT-378
was .95%.
HSA and AGP were dissolved in 67 mM phosphate
260 MOLLA ET AL.
buffer (pH 7.4) at a concentration of 40 and 0.8 mg/ml,
respectively. The binding affinity of protease inhibitors
was determined in a Spectrum equilibrium dialysis sys-
tem (Spectrum Medical Industries, Los Angeles, CA)
using 1-ml cells and a Spectra/Por 2 membrane with a
molecular weight cut-off of 12,000–14,000. Cells were
filled with a phosphate buffer on the right side and HSA
or AGP solution containing different concentrations of
radiolabeled inhibitor on the left side. The cell carrier
was rotated at about 20 rpm for 3 h in a water bath
maintained at 37°C. The stability of both drugs during 3 h
of incubation at 37°C in the presence of plasma compo-
nents was also examined. HPLC analysis indicated that
both drugs were stable during equilibrium dialysis. At
each time point, samples were removed from each side
of the cell and saved for radioassay. Duplicate aliquots of
samples were assayed directly in Insta-Gel (Packard
Instruments, Meriden, CO) scintillation cocktail and
counted in a Tri-Carb (Packard) Model 2500TR Liquid
Scintillation analyzer.
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